vs
爵士制药（JAZZ）与VEON Ltd.（VEON）财务数据对比。点击上方公司名可切换其他公司
爵士制药的季度营收约是VEON Ltd.的1.1倍（$1.2B vs $1.1B），VEON Ltd.净利率更高（55.9% vs 17.0%，领先39.0%），爵士制药同比增速更快（10.1% vs 5.8%）
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
VEON集团是一家跨国电信及数字服务企业，总部位于迪拜，在美国纳斯达克上市。公司业务覆盖欧亚6个市场，包括孟加拉国、哈萨克斯坦、吉尔吉斯斯坦、巴基斯坦、乌克兰和乌兹别克斯坦，旗下拥有孟加拉国Banglalink、巴基斯坦Jazz、乌克兰Kyivstar，以及独联体地区的Beeline等多个知名电信品牌。
JAZZ vs VEON — 直观对比
营收规模更大
JAZZ
是对方的1.1倍
$1.1B
营收增速更快
JAZZ
高出4.2%
5.8%
净利率更高
VEON
高出39.0%
17.0%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.1B |
| 净利润 | $203.5M | $608.0M |
| 毛利率 | — | — |
| 营业利润率 | 21.2% | 75.4% |
| 净利率 | 17.0% | 55.9% |
| 营收同比 | 10.1% | 5.8% |
| 净利润同比 | 6.5% | 583.1% |
| 每股收益（稀释后） | $3.34 | $0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JAZZVEON
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $897.8M | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.0B | $1.0B | ||
| Q1 24 | $902.0M | — |
净利润JAZZVEON
| Q4 25 | $203.5M | — | ||
| Q3 25 | $251.4M | — | ||
| Q2 25 | $-718.5M | $608.0M | ||
| Q1 25 | $-92.5M | — | ||
| Q4 24 | $191.1M | — | ||
| Q3 24 | $215.1M | — | ||
| Q2 24 | $168.6M | $89.0M | ||
| Q1 24 | $-14.6M | — |
营业利润率JAZZVEON
| Q4 25 | 21.2% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -65.6% | 75.4% | ||
| Q1 25 | -6.2% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 24.7% | — | ||
| Q2 24 | 19.5% | 27.1% | ||
| Q1 24 | 7.3% | — |
净利率JAZZVEON
| Q4 25 | 17.0% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | -68.7% | 55.9% | ||
| Q1 25 | -10.3% | — | ||
| Q4 24 | 17.6% | — | ||
| Q3 24 | 20.4% | — | ||
| Q2 24 | 16.5% | 8.7% | ||
| Q1 24 | -1.6% | — |
每股收益（稀释后）JAZZVEON
| Q4 25 | $3.34 | — | ||
| Q3 25 | $4.08 | — | ||
| Q2 25 | $-11.74 | $0.34 | ||
| Q1 25 | $-1.52 | — | ||
| Q4 24 | $2.97 | — | ||
| Q3 24 | $3.42 | — | ||
| Q2 24 | $2.49 | $0.04 | ||
| Q1 24 | $-0.23 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $1.3B |
| 总债务越低越好 | $5.4B | — |
| 股东权益账面价值 | $4.3B | $1.5B |
| 总资产 | $11.7B | $8.5B |
| 负债/权益比越低杠杆越低 | 1.24× | — |
8季度趋势，按日历期对齐
现金及短期投资JAZZVEON
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $1.4B | $862.0M | ||
| Q1 24 | $1.4B | — |
总债务JAZZVEON
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
股东权益JAZZVEON
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $3.7B | $1.5B | ||
| Q1 25 | $4.2B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $3.8B | $1.1B | ||
| Q1 24 | $3.7B | — |
总资产JAZZVEON
| Q4 25 | $11.7B | — | ||
| Q3 25 | $11.4B | — | ||
| Q2 25 | $10.9B | $8.5B | ||
| Q1 25 | $11.5B | — | ||
| Q4 24 | $12.0B | — | ||
| Q3 24 | $12.3B | — | ||
| Q2 24 | $11.4B | $7.3B | ||
| Q1 24 | $11.3B | — |
负债/权益比JAZZVEON
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $362.5M | — |
| 自由现金流经营现金流 - 资本支出 | $345.8M | — |
| 自由现金流率自由现金流/营收 | 28.9% | — |
| 资本支出强度资本支出/营收 | 1.4% | — |
| 现金转化率经营现金流/净利润 | 1.78× | — |
| 过去12个月自由现金流最近4个季度 | $1.3B | — |
8季度趋势，按日历期对齐
经营现金流JAZZVEON
| Q4 25 | $362.5M | — | ||
| Q3 25 | $474.6M | — | ||
| Q2 25 | $88.9M | — | ||
| Q1 25 | $429.8M | — | ||
| Q4 24 | $398.6M | — | ||
| Q3 24 | $398.7M | — | ||
| Q2 24 | $331.4M | — | ||
| Q1 24 | $267.2M | — |
自由现金流JAZZVEON
| Q4 25 | $345.8M | — | ||
| Q3 25 | $459.4M | — | ||
| Q2 25 | $75.9M | — | ||
| Q1 25 | $415.9M | — | ||
| Q4 24 | $385.3M | — | ||
| Q3 24 | $388.0M | — | ||
| Q2 24 | $324.3M | — | ||
| Q1 24 | $260.3M | — |
自由现金流率JAZZVEON
| Q4 25 | 28.9% | — | ||
| Q3 25 | 40.8% | — | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | 46.3% | — | ||
| Q4 24 | 35.4% | — | ||
| Q3 24 | 36.8% | — | ||
| Q2 24 | 31.7% | — | ||
| Q1 24 | 28.9% | — |
资本支出强度JAZZVEON
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.8% | — |
现金转化率JAZZVEON
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
VEON
暂无分部数据
